Vaxcyte Announced Topline Results From Phase 1/2 Study Of VAX-31, The Company's 31-valent Pneumococcal Conjugate Vaccine Candidate; At All Doses, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses For All 31 Serotypes
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte announced positive results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The vaccine showed strong immune responses and a good safety profile, meeting regulatory criteria. Vaxcyte plans to advance to Phase 3 trials for adults and initiate a Phase 2 study for infants.

September 03, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxcyte's VAX-31 vaccine candidate demonstrated strong immune responses and a favorable safety profile in Phase 1/2 trials, meeting regulatory criteria. The company plans to advance to Phase 3 trials for adults and initiate a Phase 2 study for infants.
The positive Phase 1/2 results for VAX-31, meeting regulatory criteria and showing a good safety profile, are likely to boost investor confidence in Vaxcyte. The advancement to Phase 3 trials and plans for further studies indicate progress and potential future revenue streams.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100